scholarly journals Polymorphisms of the stem cell marker geneCD133are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients

BMJ Open ◽  
2017 ◽  
Vol 7 (8) ◽  
pp. e016913
Author(s):  
Qing-Feng Liu ◽  
Zhi-Fei Zhang ◽  
Guang-Jie Hou ◽  
Guang-Yu Yang ◽  
Yi He
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Previous History ◽  
Small Cell ◽  
Stem Cell Marker ◽  
Nucleotide Polymorphisms ◽  
Small Cell Lung ◽  
Curative Intent ◽  
Nsclc Patients

ObjectivesTo evaluate the prognostic relevance of four functional single nucleotide polymorphisms (SNPs) inCD133(rs2240688A>C,rs10022537T>A,rs7686732C>G, andrs3130C>T) on overall survival (OS) of non-small cell lung cancer (NSCLC) patients.DesignRetrospective cohort study.SettingDepartment of General Surgery, in a general hospital, Henan Province, China.ParticipantsNSCLC patients aged ≥18 years, who were not receiving preoperative neoadjuvant therapies and had a blood sample available for genotyping, were eligible for inclusion. Those participants who were pregnant or breastfeeding, had a previous history of cancer, had other primary tumours, or who had had primary tumours of the skin and nasopharynx, were excluded from the study.Outcome measuresThe primary endpoint was OS, which was calculated from the date of enrolment until the date of death or date of last follow-up.ResultsThere was a total of 1383 participants, with a median age of 63 years; 726 (52.5%) were male. Compared with thers2240688AA genotype, the variant AC/CC genotypes were independently associated with OS (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95% CI 1.91 to 2.80 for CC genotype). Higher hazard ratios for associations betweenCD133 rs2240688polymorphism and OS were observed in patients with adjuvant chemotherapy (HR 1.86, 95% CI 1.52 to 2.26) and radiotherapy for curative intent (HR 1.90, 95% CI 1.55 to 2.33).ConclusionsThe study confirmed the significant association between the SNPrs2240688 A>Cof CD133 and OS of NSCLC patients. Larger population-based studies in different ethnic groups are necessary to further validate the role and mechanisms ofCD133in NSCLC.

scholarly journals The prognostic roles of circulating ALDH1+ tumor cell in the patients with non-small cell lung cancer

2018 ◽  
Vol 38 (5) ◽  
Author(s):  
Shuang Tian ◽  
Ya-Nan Xing ◽  
Pu Xia
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stem Cell Marker ◽  
Small Cell Lung ◽  
Nsclc Patients

Circulating tumor cells can provide important diagnostic and prognostic information of the patients with non-small cell lung cancer (NSCLC). Aldehyde dehydrogenase 1 (ALDH1), a cancer stem cell marker, has been used in various tumors, including NSCLC. In the present study, we isolated the circulating ALDH1+ tumor cells from the NSCLC patients using ALDH1 as a potential marker. Higher percentage of ALDH1+ tumor cells was identified in blood samples from the NSCLC patients compared with normal controls. ALDH1+ cells were correlated with the poor prognosis of these patients by using Kaplan–Meier analysis. In the last, the tumorigenic properties of ALDH1+ tumor cells were determined in vitro and in vivo by using sphere assay and xenograft tumor mouse models. Our in vitro and in vivo experiments demonstrated that ALDH1 could drive the stemness of circulating NSCLC cells. Circulating ALDH1+ cells could be used as a prognostic marker for NSCLC.

scholarly journals The miR-146a SNP Rs2910164 and miR-155 SNP rs767649 are risk factors for non- small cell lung cancer in Iranian population

2020 ◽  
Author(s):  
Neda KakaDezfuli ◽  
Ian M. Adcock ◽  
Shamila D. Alipour ◽  
Sharareh Seyfi ◽  
Babak Salimi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Genomic Region ◽  
Small Cell ◽  
Iranian Population ◽  
Control Group ◽  
Nucleotide Polymorphisms ◽  
Small Cell Lung ◽  
Nsclc Patients

Abstract Background: Lung cancer is a leading cause of death worldwide. MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and may act as both tumor suppressors and as oncogenes. The presence of single nucleotide polymorphisms (SNPs) inside the miRNA genomic region could affect target miRNA maturation, expression and binding to its target mRNA and contribute to cancer development. Previous studies on the SNPs Rs2910164 in miR-146a and Rs767649 in miR-155 showed association with non-small cell lung cancer (NSCLC) development. Thus, the aim of study was to detect any correlation between those SNPs in Iranian NSCLC patients.Methods: In a small cohort study, 165 NSCLC patients and 147 non-cancer controls were enrolled between Apr 2015 – Sep 2019 at the Masih Daneshvari Hospital, Tehran-Iran. Allele frequencies from genomic DNA of blood PBMC was studied using PCR-RFLP and their association with the risk of lung cancer was evaluated.Results: The frequency of the C allele of the miR-146a rs2910164 polymorphism was increased in NSCLC patients (OR=1.56, 95%CI=1.10 -2.21, P= 0.012). In contrast, the frequency of the A allele of the miR-155 rs767649 polymorphism was significantly increased in the control group (TT vs. AA+AT: OR=0.58, 95%CI=0.35-0.98, P= 0.043).Conclusion: The findings of this study suggest that miR-146a rs2910164 and miR-155 rs767649 polymorphisms could be related with the risk of NSCLC in an Iranian population. However, a larger multi center study across Iran is needed to confirm these findings.

scholarly journals Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3828
Author(s):  
Anello Marcello Poma ◽  
Rossella Bruno ◽  
Iacopo Pietrini ◽  
Greta Alì ◽  
Giulia Pasquini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Cell ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Durable Response ◽  
Nsclc Patients

Pembrolizumab has been approved as first-line treatment for advanced Non-small cell lung cancer (NSCLC) patients with tumors expressing PD-L1 and in the absence of other targetable alterations. However, not all patients that meet these criteria have a durable benefit. In this monocentric study, we aimed at refining the selection of patients based on the expression of immune genes. Forty-six consecutive advanced NSCLC patients treated with pembrolizumab in first-line setting were enrolled. The expression levels of 770 genes involved in the regulation of the immune system was analysed by the nanoString system. PD-L1 expression was evaluated by immunohistochemistry. Patients with durable clinical benefit had a greater infiltration of cytotoxic cells, exhausted CD8, B-cells, CD45, T-cells, CD8 T-cells and NK cells. Immune cell scores such as CD8 T-cell and NK cell were good predictors of durable response with an AUC of 0.82. Among the immune cell markers, XCL1/2 showed the better performance in predicting durable benefit to pembrolizumab, with an AUC of 0.85. Additionally, CD8A, CD8B and EOMES showed a high specificity (>0.86) in identifying patients with a good response to treatment. In the same series, PD-L1 expression levels had an AUC of 0.61. The characterization of tumor microenvironment, even with the use of single markers, can improve patients’ selection for pembrolizumab treatment.

scholarly journals P09.22 Curative Intent Treatment for Small Cell Lung Cancer in England

2021 ◽  
Vol 16 (3) ◽  
pp. S298-S299
Author(s):  
S. Harden ◽  
E. Peach ◽  
P. Beckett ◽  
N. Navani
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Curative Intent
Sign in / Sign up

Export Citation Format

Share Document